Skip to main content

Featured

Gingerbread Cookies

These cookies are warmly spiced, with crisp edges and soft centers—perfect for holiday decorating and eating. Ingredients 3 cups all-purpose flour ¾ teaspoon baking soda ¼ teaspoon salt 1 tablespoon ground ginger 1 tablespoon ground cinnamon ½ teaspoon ground cloves ½ teaspoon ground nutmeg 8 tablespoons (1 stick) unsalted butter, softened ¾ cup packed dark brown sugar ¾ cup unsulfured molasses 1 large egg Instructions Mix dry ingredients : In a medium bowl, whisk flour, baking soda, salt, and spices. Cream butter & sugar : In a large bowl, beat butter and brown sugar until fluffy. Add molasses and egg. Combine : Gradually add dry mixture until dough forms. Chill dough : Divide into two disks, wrap in plastic, and refrigerate for at least 1 hour. Roll & cut : Roll dough to ¼-inch thickness. Cut into shapes with cookie cutters. Bake : Place on parchment-lined sheets and bake at 350°F for 8–10 minutes, until edges are set. Cool & decorate : Let cool com...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment